Tolvaptan Safety and Efficacy in Later-Stage ADPKD

REPRISE

Patient / Population Intervention / Exposure Comparison Outcome

In 1,370 patients with later-stage ADPKD, tolvaptan slowed eGFR decline compared with placebo.

N

1,370patients

Design

Double-blind RCT over 12 months

Endpoint

Change in eGFR from baseline

Relevance

3Supporting — context rather than must-know.

Result−2.34 vs −3.61 mL/min/1.73m²/yr; difference 1.27 (95% CI 0.86–1.68; p<0.001).

Torres VE, et al. N Engl J Med. 2017;377(20):1930-1942. 10.1056/NEJMoa1710030

Cited in guidelines

Discussion & critique

Extended the tolvaptan indication to more advanced CKD stages of ADPKD.